Vincent P. Laudone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vincent P. Laudone has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Michael J. Morris
Memorial Sloan Kettering Cancer Center, New York, NY
17 shared publications - Andrew T. Lenis
Columbia University, New York, New York
16 shared publications - Anuradha Gopalan
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
16 shared publications - Dana E. Rathkopf
Memorial Sloan Kettering Cancer Center, New York, USA
16 shared publications - Daniel Costin Danila
Memorial Sloan Kettering Cancer Center, New York, NY
16 shared publications - David B. Solit
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
16 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (9)
Effect of Acupuncture on Urine Production and Storage in Prostate Cancer Survivors With Nocturia: Exploratory Analysis of a Randomized Clinical Trial
Background: Nocturia is multifactorial condition, but most treatments only target urine production or storage in isolation. Acupuncture has been shown to decrease nocturia, but its mechanisms remain unclear. This study explores the preliminary effects of acupuncture on urine production and storage to inform future mechanistic hypotheses. Methods: We conducted a secondary analysis of 3-day frequency volume charts from a clinical trial in which prostate cancer survivors with nocturia were randomized to receive acupuncture or usual care (waitlist control [WLC]). Within-group posttreatment changes and between-group differences were compared by paired and two-sample t-tests in the total sample and in subgroups stratified by the presence of nocturnal polyuria at baseline. Results: In the total sample (N = 35), acupuncture reduced nocturia episodes (−1.1 vs −0.4, P = .016) and increased mean urine volume per nighttime void (+30.3 mL vs −0.6 mL, P = .047) relative to the WLC group. In the subgroup with nocturnal polyuria, acupuncture reduced nocturia episodes (−1.1, P = .0057) and reduced the ratio of nocturnal urine volume to total urine volume (−10.7%, P = .02); nocturia episodes also decreased in the WLC group (−0.4, P = .018), but there was no significant change in the ratio of nocturnal urine volume to total urine volume. Conclusions: Among prostate cancer survivors with nocturia, acupuncture demonstrated joint effects on urine production and storage. Acupuncture also reduced nocturia across different types of underlying urinary dysfunction, including nocturnal polyuria. If confirmed, these preliminary findings could inform a novel treatment approach uniquely suited for the multifactorial etiology of nocturia.
- 1 September 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (9)
Open AccessEffect of Acupuncture on Urine Production and Storage in Prostate Cancer Survivors With Nocturia: Exploratory Analysis of a Randomized Clinical Trial
Background: Nocturia is multifactorial condition, but most treatments only target urine production or storage in isolation. Acupuncture has been shown to decrease nocturia, but its mechanisms remain unclear. This study explores the preliminary effects of acupuncture on urine production and storage to inform future mechanistic hypotheses. Methods: We conducted a secondary analysis of 3-day frequency volume charts from a clinical trial in which prostate cancer survivors with nocturia were randomized to receive acupuncture or usual care (waitlist control [WLC]). Within-group posttreatment changes and between-group differences were compared by paired and two-sample t-tests in the total sample and in subgroups stratified by the presence of nocturnal polyuria at baseline. Results: In the total sample (N = 35), acupuncture reduced nocturia episodes (−1.1 vs −0.4, P = .016) and increased mean urine volume per nighttime void (+30.3 mL vs −0.6 mL, P = .047) relative to the WLC group. In the subgroup with nocturnal polyuria, acupuncture reduced nocturia episodes (−1.1, P = .0057) and reduced the ratio of nocturnal urine volume to total urine volume (−10.7%, P = .02); nocturia episodes also decreased in the WLC group (−0.4, P = .018), but there was no significant change in the ratio of nocturnal urine volume to total urine volume. Conclusions: Among prostate cancer survivors with nocturia, acupuncture demonstrated joint effects on urine production and storage. Acupuncture also reduced nocturia across different types of underlying urinary dysfunction, including nocturnal polyuria. If confirmed, these preliminary findings could inform a novel treatment approach uniquely suited for the multifactorial etiology of nocturia.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Table 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Table 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Table 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Table 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 4 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 4 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Table 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Table 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer